INNOCARE PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.45 HKD | +1.37% |
|
+9.61% | -35.41% |
| Sales 2024 * | 849M 117M 917M | Sales 2025 * | 1.3B 180M 1.41B | Capitalization | 8.37B 1.15B 9.04B |
|---|---|---|---|---|---|
| Net income 2024 * | -675M -93.16M -729M | Net income 2025 * | -487M -67.21M -526M | EV / Sales 2024 * | -1.44 x |
| Net cash position 2024 * | 9.59B 1.32B 10.36B | Net cash position 2025 * | 11.92B 1.65B 12.88B | EV / Sales 2025 * | -2.73 x |
| P/E ratio 2024 * |
-10.1
x | P/E ratio 2025 * |
-15.2
x | Employees | 1,089 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 56.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on InnoCare Pharma Limited
More press releases
| 1 day | +1.37% | ||
| 1 week | +9.61% | ||
| Current month | -4.30% | ||
| 1 month | -5.72% | ||
| 3 months | -19.68% | ||
| 6 months | -16.98% | ||
| Current year | -35.41% |
1 week
4.05
4.48
1 month
4.035.06
Current year
4.036.95
1 year
4.039.60
3 years
4.0332.05
5 years
4.0332.05
10 years
4.0332.05
| Managers | Title | Age | Since |
|---|---|---|---|
Jisong Cui
CEO | Chief Executive Officer | 62 | 15-11-02 |
Xin Fu
DFI | Director of Finance/CFO | 46 | Dec. 17 |
Kevin Gao
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yigong Shi
FOU | Founder | 57 | 15-11-02 |
Kai Xian Chen
BRD | Director/Board Member | 79 | 20-02-29 |
Jisong Cui
CEO | Chief Executive Officer | 62 | 15-11-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.14% | 4 M€ | -27.92% | ||
| 0.13% | 2 M€ | -14.14% | ||
| 0.01% | 117 M€ | +1.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4.45 | +1.37% | 2,792,000 |
| 24-04-25 | 4.39 | +1.39% | 2,266,000 |
| 24-04-24 | 4.33 | +2.61% | 2,904,000 |
| 24-04-23 | 4.22 | +0.48% | 3,671,000 |
| 24-04-22 | 4.2 | +3.45% | 4,038,504 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am EDT
More quotes
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The Company mainly conducts its businesses in domestic and overseas markets.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.119
CNY
Average target price
8.987
CNY
Spread / Average Target
+118.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.41% | 1.15B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 9969 Stock
